Previously untreated chronic lymphocytic leukemia (CLL) patients experienced increased progression-free and overall survival when treated with ibrutinib-rituximab compared to current standard chemoimmunotherapy. Rates of high grade adverse events were sim
Just a nice double burger from Budapest ????
